For the quarter ending 2026-03-31, ALNY has $5,129,547K in assets. $4,054,167K in debts. $1,710,779K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Marketable equity securities | - | 0 | 0 | 0 |
| Cash and cash equivalents | 1,710,779 | 1,657,250 | 1,490,249 | 1,113,685 |
| Marketable debt securities | 1,298,444 | 1,251,234 | 1,234,375 | 1,743,900 |
| Accounts receivable, net | 883,957 | 777,567 | 964,768 | 567,112 |
| Inventory | 84,025 | 82,719 | 75,383 | 71,688 |
| Prepaid expenses and other current assets | 242,103 | 281,892 | 188,036 | 147,314 |
| Total current assets | 4,219,308 | 4,050,662 | 3,952,811 | 3,643,699 |
| Property, plant and equipment, net | 518,257 | 513,147 | 501,754 | 499,791 |
| Operating lease right-of-use assets | 189,299 | 194,916 | 191,390 | 192,401 |
| Deferred tax assets | 116,960 | 125,975 | 98,558 | 104,363 |
| Restricted investments | 22,170 | 22,170 | 51,314 | 68,593 |
| Other assets | 63,553 | 59,461 | 55,835 | 57,172 |
| Total assets | 5,129,547 | 4,966,331 | 4,851,662 | 4,566,019 |
| Accounts payable | 126,628 | 115,721 | 117,591 | 102,393 |
| Accrued expenses | 946,485 | 1,080,197 | 1,153,648 | 918,966 |
| Operating lease liabilities | 45,661 | 45,518 | 44,755 | 46,097 |
| Liability related to the sale of future royalties | - | - | 115,691 | 97,523 |
| Development derivative liability | - | 0 | 121,251 | 120,788 |
| Deferred revenue | 3,213 | 4,845 | 2,541 | 15,080 |
| Liabilities related to the sale of future royalties and development funding | 227,488 | 220,068 | - | - |
| Total current liabilities | 1,349,475 | 1,466,349 | 1,555,477 | 1,300,847 |
| Operating lease liabilities, net of current portion | 218,025 | 225,087 | 223,421 | 224,445 |
| Liability related to the sale of future royalties, net of current portion | - | - | 1,349,166 | 1,345,147 |
| Development derivative liability, net of current portion | - | 0 | 439,659 | 407,535 |
| Convertible debt | 1,009,372 | 1,007,784 | 1,040,276 | 1,026,522 |
| Liabilities related to the sale of future royalties and development funding, net of current portion | 1,469,684 | 1,470,341 | - | - |
| Other liabilities | 7,611 | 7,594 | 9,769 | 10,932 |
| Total liabilities | 4,054,167 | 4,177,155 | 4,617,768 | 4,315,428 |
| Common stock, 0.01 par value per share, 250,000 shares authorized 133,444 shares issued and outstanding as of march31, 2026 132,376 shares issued and outstanding as of december31, 2025 | 1,334 | 1,324 | 1,318 | 1,310 |
| Additional paid-in capital | 7,595,473 | 7,510,473 | 7,414,771 | 7,690,737 |
| Accumulated other comprehensive loss | -24,894 | -20,097 | -21,775 | -29,952 |
| Accumulated deficit | -6,496,533 | -6,702,524 | -7,160,420 | -7,411,504 |
| Total stockholders' equity | 1,075,380 | 789,176 | 233,894 | 250,591 |
| Total liabilities and stockholders' equity | 5,129,547 | 4,966,331 | 4,851,662 | 4,566,019 |
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)